(R)-nocardione B | 396659-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: (R)-nocardione B
• 英文别名: (R)-(+)-2,3-dihydro-6-methoxy-2-methylnaphtho[1,2-b]furan-4,5-dione；(2R)-6-methoxy-2-methyl-2,3-dihydrobenzo[g][1]benzofuran-4,5-dione
• CAS: 396659-84-0
• 化学式: C₁₄H₁₂O₄
• 分子量: 244.247
• InChiKey: VIEJGPLASHRUTP-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-nocardione B 在 三氯化铝 作用下， 以 二氯甲烷 为溶剂， 反应 13.5h， 以236 mg的产率得到(+/-)-nocardione A
  参考文献：
  名称：

  Synthesis and Absolute Configuration of Nocardione A and B, Furano-o-naphthoquinone-Type Metabolites of Nocardia sp. with Antifungal, Cytotoxic, and Enzyme Inhibitory Activities

  摘要：

  (±)-Nocardione A (1), (S)-(-)-nocardione A 和 (R)-(+)-nocardione B (2) 通过以丙二醇环氧丙烷和 5-苄氧基（或甲氧基）-1-四氢萘酮的对映体为起始原料进行合成。天然存在的 (-)-1 和 (-)-2 的绝对构型均被确定为 (S)。

  DOI：

  10.1002/1099-0690(200111)2001:22<4313::aid-ejoc4313>3.0.co;2-j
• 作为产物：
  描述：

  (S)-(+)-2-(2'-hydroxypropyl)-5-methoxy-1,4-naphthalenediol 在 benzeneselenenic anhydride 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 19.5h， 生成 (R)-nocardione B
  参考文献：
  名称：

  Synthesis and Absolute Configuration of Nocardione A and B, Furano-o-naphthoquinone-Type Metabolites of Nocardia sp. with Antifungal, Cytotoxic, and Enzyme Inhibitory Activities

  摘要：

  (±)-Nocardione A (1), (S)-(-)-nocardione A 和 (R)-(+)-nocardione B (2) 通过以丙二醇环氧丙烷和 5-苄氧基（或甲氧基）-1-四氢萘酮的对映体为起始原料进行合成。天然存在的 (-)-1 和 (-)-2 的绝对构型均被确定为 (S)。

  DOI：

  10.1002/1099-0690(200111)2001:22<4313::aid-ejoc4313>3.0.co;2-j

文献信息

• Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases
  申请人：Yoo Sang-Ku

  公开号：US20080146655A1

  公开（公告）日：2008-06-19

  Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供一种药物组合物，用于治疗和预防肥胖、糖尿病、代谢综合征、退行性疾病和线粒体功能障碍相关疾病，包括：以下式I所表示的化合物的治疗有效量，或其药学上可接受的盐、前药、溶剂或异构体，以及药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES
  申请人：Yoo Sang-Ku

  公开号：US20090292011A1

  公开（公告）日：2009-11-26

  Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种用于治疗和预防肥胖、糖尿病、代谢综合征、退行性疾病以及线粒体功能障碍相关疾病的制药组合物，包含以下公式I所表示的化合物的治疗有效量，或其药学上可接受的盐、前药、溶剂或异构体，以及药学上可接受的载体、稀释剂或赋形剂，或任何组合。
• NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME
  申请人：Yoo Sang-Ku

  公开号：US20100137422A1

  公开（公告）日：2010-06-03

  Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种用于治疗和/或预防涉及代谢综合征的疾病的制药组合物，包括(a)根据规范中定义的公式1所代表的特定化合物的治疗有效量，或其异构体，前药或溶剂或其任意组合物，以及(b)药学上可接受的载体，稀释剂或赋形剂，或其任意组合物。
• COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME
  申请人：Kwak Taehwan

  公开号：US20100239685A1

  公开（公告）日：2010-09-23

  Provided is a naphthoquinone-based compound represented by Formula 1 or 2 having therapeutic effect on the treatment and/or prevention of prostate and/or testicle (seminal glands)-related diseases, and to a pharmaceutical composition of intestinal delivery system containing the same.
• US8404869B2
  申请人：——

  公开号：US8404869B2

  公开（公告）日：2013-03-26